SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-21-014772
Filing Date
2021-04-28
Accepted
2021-04-28 16:32:03
Documents
5
Period of Report
2021-06-16

Document Format Files

Seq Description Document Type Size
1 DEF 14A nc10021152x1_def14a.htm DEF 14A 1054592
2 logo_cytomx.jpg GRAPHIC 35885
3 nc10021152x1_diagram01.jpg GRAPHIC 321025
4 nc10021152x1_pc01.jpg GRAPHIC 461113
5 nc10021152x1_pc02.jpg GRAPHIC 395169
  Complete submission text file 0001140361-21-014772.txt   2725505
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37587 | Film No.: 21864729
SIC: 2834 Pharmaceutical Preparations